Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications
Van Zandt, M.C., Jones, M.L., Gunn, D.E., Geraci, L.S., Jones, J.H., Sawicki, D.R., Sredy, J., Jacot, J.L., Dicioccio, A.T., Petrova, T., Mitschler, A., Podjarny, A.D.(2005) J Med Chem 48: 3141-3152
- PubMed: 15857120 
- DOI: https://doi.org/10.1021/jm0492094
- Primary Citation of Related Structures:  
1Z3N - PubMed Abstract: 
Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes ...